Claudia Oliveira

Claudia Oliveira

Auto-generated profile, based on publicly available information

Claudia Oliveira

Group Genetics of Cognitive Dysfunction, IBMC - Instituto de Biologia Molecular e Celular, I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, Porto, Portugal

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ASAna I. Seixas
Ana I. Seixas
JLJoana R Loureiro
Joana R Loureiro
CCCristina Costa
Cristina Costa
AOAndrés Ordóñez-Ugalde
Andrés Ordóñez-Ugalde
HMHugo Marcelino
Hugo Marcelino
Isabel SilveiraIsabel Silveira
Isabel Silveira

1 August 2016 in Carbohydrate Polymers
Verified
Journal Article
Closed access
ARAntonio Ribeiro
Antonio Ribeiro
FSFlávia R. Lucena de Souza
Flávia R. Lucena de Souza
JBJanira M.N.A. Bezerra
Janira M.N.A. Bezerra
COClaudia Oliveira
Claudia Oliveira
DNDaniela Nadvorny
Daniela Nadvorny
JSJosé Lamartine Soares Sobrinho
José Lamartine Soares Sobrinho

1 March 2016 in Neurobiology of Aging
Verified
Journal Article
Closed access
JLJoana R Loureiro
Joana R Loureiro
COClaudia L. Oliveira
Claudia L. Oliveira
Isabel SilveiraIsabel Silveira
Isabel Silveira

1 May 2016 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
COCláudia Oliveira
Cláudia Oliveira
ARAntonio Ribeiro
Antonio Ribeiro
Francisco VeigaFrancisco Veiga
Francisco Veiga
Isabel SilveiraIsabel Silveira
Isabel Silveira
Delivery of nucleic acids is the most promising therapy for many diseases that remain untreatable. Therefore, many research efforts have been put on finding a safe and efficient delivery system able to provide a sustained response. Viral vectors have proved to be the most efficient for delivery of nucleic acids and, thus, stand as the foremost vector used in current clinical trials. However, safety issues arise as a main concern and mitigate their use, impelling the improvement of non-viral alternatives. This review focuses on the recent advances in pre-clinical development of non-viral polyplexes and lipoplexes for nucleic acid-based delivery, in contrast with vectors being used in present clinical trials. Nucleic acid vectors for neurodegenerative ataxias, Parkinson's disease, retinitis pigmentosa, cystic fibrosis, hemophilia, pancreatic and lung cancer, and rheumatoid arthritis are discussed to illustrate current state of pre-clinical and clinical studies. Thereby, denoting the prospects for treatment of genetic diseases and elucidating the trend in non-viral vector development and improvement which is expected to significantly increase disease rescue exceeding the modest clinical successes observed so far.

1 February 2017 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
COClaudia L. Oliveira
Claudia L. Oliveira
Francisco VeigaFrancisco Veiga
Francisco Veiga
CVCarla Varela
Carla Varela
FRFernanda M.F. Roleira
Fernanda M.F. Roleira
ESElisiário Tavares da Silva
Elisiário Tavares da Silva
ARAntonio Ribeiro
Antonio Ribeiro

1 September 2015 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ARAntonio Ribeiro
Antonio Ribeiro
MLMarlene Lopes
Marlene Lopes
BABárbara Abrahim-Vieira
Bárbara Abrahim-Vieira
Pedro FontePedro Fonte
Pedro Fonte
ASAlessandra Souza
Alessandra Souza
COClaudia Oliveira
Claudia Oliveira
Alginate–dextran sulfate-based particles obtained by emulsification/internal gelation technology can be considered suitable carriers for oral insulin delivery. A rational study focused on the emulsification and particle recovery steps was developed in order to reduce particles to the nanosize range while keeping insulin bioactivity. There was a decrease in size when ultrasonication was used during emulsification, which was more pronounced when a cosurfactant was added. Ultrasonication add-on after particle recovery decreased aggregation and led to a narrower nanoscale particle-size distribution. Insulin encapsulation efficiency was 99.3%±0.5%, attributed to the strong pH-stabilizing electrostatic effect between insulin and nanoparticle matrix polymers. Interactions between these polymers and insulin were predicted using molecular modeling studies through quantum mechanics calculations that allowed for prediction of the interaction model. In vitro release studies indicated well-preserved integrity of nanoparticles in simulated gastric fluid. Circular dichroism spectroscopy proved conformational stability of insulin and Fourier transform infrared spectroscopy technique showed rearrangements of insulin structure during processing. Moreover, in vivo biological activity in diabetic rats revealed no statistical difference when compared to nonencapsulated insulin, demonstrating retention of insulin activity. Our results demonstrate that alginate–dextran sulfate-based nanoparticles efficiently stabilize the loaded protein structure, presenting good physical properties for oral delivery of insulin.